Dear Client,
As part of our ongoing commitment to ensuring the security of your online trading experience, we would like to inform you of our protocol for addressing any suspicious activities observed on your trading account.
Should you notice any irregularities or suspect unauthorized access to your account, we kindly request that you take immediate action by following the steps outlined below:
Send an EmailPlease send an email to stoptrade@acml.infrom your registered email ID. In the email, briefly outline the suspicious activity you have observed.
Phone Call Alternatively, you can call us at 07965081981 Ext: 4 from your registered mobile number. This will enable us to address your concerns promptly.
When contacting us, please ensure you provide the following details:
By providing this information, you enable us to swiftly investigate and take appropriate measures to safeguard your account.
Your security and peace of mind are of utmost importance to us,and we appreciate your cooperation in maintaining the integrity of your trading account.
Sun Pharmaceutical Industries Ltd announced today that CRISIL Ratings has reaffirmed its ratings on the company, including the long-term rating of "CRISIL AAA/Stable" and the short-term rating of "CRISIL A1+," while simultaneously withdrawing the ratings as they are no longer required by the rated entity; India Ratings & Research (Ind-Ra) has also reaffirmed its ratings, assigning a long-term rating of "IND AAA (Stable)" and a short-term rating of "IND A1+"; furthermore, CARE Ratings has reaffirmed its ratings, maintaining a long-term rating of "CRISIL AAA (Stable)" and a short-term rating of "CRISIL A1+," with a standalone credit watch positive; these ratings cover bank loan facilities aggregating to INR 27,000 crore, commercial paper of INR 2,000 crore, and preference shares amounting to INR 1,000 crore, with the reaffirmations reflecting Sun Pharma’s strong financial risk profile and market position, and the withdrawals by CRISIL are solely due to the company’s request.